CCELHealthcare · Medical Care FacilitiesTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 76 of 100 as at 14 Oct 2026 — inside the top quartile.
Consensus tells you what everyone already believes. The model scores Cryo-Cell International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2025 | Maxim Group | Downgrade | Hold | — |
| 4 Mar 2025 | Maxim Group | Maintains | Buy | — |
| 29 Aug 2022 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CCEL appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Cryo-Cell International, Inc. returned −8.6% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 2% of US stocks
Cheaper than 66% of US stocks
Cheaper than 95% of US stocks
Cheaper than 7% of US stocks
Higher than 30% of US stocks
Higher than 79% of US stocks
Higher than 90% of US stocks
Higher than 86% of US stocks
Higher than 23% of US stocks
Higher than 71% of US stocks
Higher than 44% of US stocks
Higher than 97% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cryo-Cell International, Inc. has a market value of $33.5M and an enterprise value of $39.3M.
Revenue in the twelve months to 31 May 2026: $31.2M. The latest quarter grew 1.2% year on year.
Net income over the same four quarters: −$2.9M, a −9.2% net margin.
Free cash flow in the twelve months to 31 May 2026: $4.3M, after $114K of capital spending.
Cryo-Cell International, Inc. spent $1.2M on dividends in the twelve months to 31 May 2026.
Trailing P/E: 475.0×; forward P/E: 207.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 14.46%, paying out 5000% of earnings.
Cryo-Cell International, Inc. employs 72 people — $434K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cryo-Cell International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Benzinga listed Cryo-Cell International among stocks that may draw investor focus on Monday, alongside Goodyear Tire and three other stocks. The item noted that U.S. stock futures were trading higher that morning.
Why it matters — The article identifies CCEL as a stock to watch, but provides no company-specific news or details about why it may attract attention.
Cryo-Cell reported fiscal third-quarter 2026 revenue of $7.82 million, compared with $7.83 million in the year-ago quarter. The company also reported net income of $1.27 million.
Why it matters — The results provide CCEL watchers with an update on quarterly revenue and profitability.
Of the 1 analysts covering Cryo-Cell International, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cryo-Cell International, Inc. 76 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Cryo-Cell International, Inc. ranks 76 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).
No analyst covering Cryo-Cell International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CCEL are extrapolating price history, which says nothing about the business.
Cryo-Cell International, Inc. returned -8.6% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Cryo-Cell International, Inc. is a healthcare services company focused on cord blood and cord tissue banking.
The most recent item we track (Benzinga, 12 Oct 2026): "Goodyear Tire, Cryo-Cell International and 3 Stocks to Watch Heading Into Monday". Benzinga listed Cryo-Cell International among stocks that may draw investor focus on Monday, alongside Goodyear Tire and three other stocks. The item noted that U.S. stock futures were trading higher that morning.
Cryo-Cell International, Inc. is a healthcare services company focused on cord blood and cord tissue banking. The company provides cellular processing and cryogenic storage for family use, centered on the collection and preservation of umbilical cord blood and tissue stem cells. It also operates a public cord blood banking segment and manufactures PrepaCyte CB processing systems used in cord blood stem cell preparation. Through these offerings, Cryo-Cell serves expectant parents, healthcare professionals, and public donation programs, supporting long-term biological storage services and regenerative medicine research infrastructure. Headquartered in Oldsmar, Florida, Cryo-Cell International remains a specialized participant in the stem cell preservation market.
CEO Mr. David I. Portnoy · 72 employees · United States · https://www.cryo-cell.com
